Commercial Model Innovation Key To Lowering China Compliance Risks
This article was originally published in PharmAsia News
Balanced scorecards, big data, and platform strategies are among the new tools being employed by pharma companies ramping up compliance and lowering risks in China, where market access remains challenging and pricing pressures persistent. Such commercial model innovation should also improve physician interaction while providing new medical solutions, said executives at a recent RDPAC gathering in Beijing.
Register for our free email digests: